Previous Close | 24.69 |
Open | 24.59 |
Bid | 25.31 x 200 |
Ask | 25.41 x 400 |
Day's Range | 24.59 - 25.55 |
52 Week Range | 17.53 - 59.84 |
Volume | |
Avg. Volume | 906,411 |
Market Cap | 1.94B |
Beta (5Y Monthly) | 0.67 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -8.37 |
Earnings Date | Apr 25, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 27.91 |
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2024 financial results and provide an update on the company's business and outlook on Thursday, April 25, at 4:30 p.m. ET.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin MAA to the European Medicines Agency. The MAA submission is for the treatment of pediatric and adult patients with PKU, including the full spectrum of disease subtypes.